Actively Recruiting
Safety and Activity Study of Single-Dose JAG201 Gene Therapy Delivered into the Brain for Children and Adults with SHANK3 Haploinsufficiency
Led by Jaguar Gene Therapy, LLC · Updated on 2026-09-03
6
Participants Needed
3
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, and clinical effects of a single dose of JAG201 gene therapy delivered directly into the brains ventricles in children and adults with SHANK3 haploinsufficiency caused by specific genetic mutations or deletions. This Phase 12 open-label trial focuses primarily on pediatric participants aged 2 to 9 years, with adult enrollment planned for later. The study aims to gather initial data on how well JAG201 is tolerated and its preliminary impact on participants conditions. Participants will receive one of two dose levels of JAG201 via intracerebroventricular injection on Day 1, following eligibility screening that may take up to 90 days. After the single-dose gene therapy administration, participants will be closely monitored in a hospital setting for safety. The study consists of five periods Pre-Screening, Screening, Gene Therapy Administration with perioperative care, Initial Follow-Up up to 2 years, and Long-Term Follow-Up through 5 years post-treatment. Throughout the trial, participants will undergo regular assessments including safety evaluations, laboratory tests, and clinical activity monitoring at scheduled visits during the follow-up phases. Researchers will track adverse events, immune responses, and changes in developmental or behavioral measures. The total participation lasts up to 5 years after treatment to ensure comprehensive safety and clinical data collection.
CONDITIONS
Brief Title
JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency
Research Team
J
Jaguar Gene Therapy
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here